已知eIF5B抑制剂在治疗急性髓系白血病（AML）中的新用途
By inhibiting the translation process of AML cells using the eIF5B inhibitor 1282NJ0069, the selectivity and differentiation methods of existing AML treatments are addressed, achieving highly efficient inhibition and differentiation of AML cells and providing a safe treatment option.
CN121287913BActive Publication Date: 2026-07-17INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
- Filing Date
- 2025-08-28
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current AML treatments suffer from insufficient selectivity of targeted drugs and a lack of effective means to induce cell differentiation, resulting in significant side effects and limited applicability.
Method used
Using the eIF5B inhibitor 1282NJ0069, drugs in the form of nucleic acid inhibitors and protein inhibitors were developed to inhibit AML cell proliferation and induce their differentiation by inhibiting the functional contact of eIF5B and weakening the translation of ribosome complexes.
Benefits of technology
eIF5B inhibitors are highly toxic to AML cells, effectively inhibiting cell proliferation and inducing differentiation, while having little effect on normal hematopoietic stem/progenitor cells, providing a safe and effective treatment option for AML.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN121287913B_ABST
Abstract
本发明公开了已知eIF5B抑制剂在治疗急性髓系白血病（AML）中的新用途。本发明首次发现eIF5B抑制剂对多种AML细胞具有高毒性，能够抑制多种AML细胞增殖，还能诱导其分化，而对正常造血干 / 祖细胞无显著影响，可用于开发治疗AML的药物。本发明为抗AML药物的研发提供了理论依据，开辟了eIF5B抑制剂的新用途，为治疗AML提供了全新的方法，在AML治疗这一技术领域具有广泛的应用前景。
Need to check novelty before this filing date? Find Prior Art